The University of Virginia Comprehensive Cancer Center seeks participants ages 18 and over with Advanced,
EGFR Mutant Cancer for a study. The purpose of this study is to learn about the safety, tolerance and effectiveness of the study drug, NX-019, at different doses to see what effects (good and bad) it has on you and your cancer. In this study, different doses of NX-019 will be given to study subjects to determine the recommended dose for treating your cancer safely.

The University of Virginia Comprehensive Cancer Center is participating to the EMN28-Emagine/CARTITUDE-6 study that is for participants ages 18 and over with Newly Diagnosed Multiple Myeloma who are Transplant Eligible and have had no prior treatment. This is a large, global study investigating the use ciltacabtagene autoleucel (cilta-cel) versus autologous stem cell transplantation (ASCT), which is the current standard of care.

The UVA Department of Kinesiology seeks adults ages 18 – 55 with plantar fasciitis or heel pain for a research study. The purpose of the study is to investigate if wearing minimalist shoes and performing rehabilitation exercises will be more beneficial in relieving pain compared to only performing rehabilitation exercises.

The University of Virginia Comprehensive Cancer Center seeks participants ages 18 and over with Limited-Stage Small-Cell Lung Cancer (LS-SCLC) who Have not Progressed Following Concurrent Chemoradiation Therapy. The purpose of this study is to see the efficacy (how well something works) of the study drug (tarlatamab/placebo) and whether it causes any side effects. Tarlatamab is an investigational drug that is being developed as an anticancer drug for tumors (abnormal growth of tissue) in SCLC. The study drug, tarlatamab will be compared with placebo.

The University of Virginia is conducting a clinical research study for adults ages 18 and over who have advanced Merkel cell skin cancer who have progressed on anti PD-(L) 1 therapy. The purpose of this study is to see is to compare the treatment of M1774 plus avelumab with M1774 alone. M1774 or the combination of M1774 plus avelumab could shrink your cancer or prevent it from returning. This is a randomized study, so you will be put into a group by chance. You will have an equal chance of being in Group 1 or Group 2:

The University of Virginia is conducting a clinical research study for patients who are adults ages 18 and over, and have non-muscle invasive bladder cancer (NMIBC) and they either have not had Bacillus Calmette-Guerin (BCG) therapy or have not responded well to BCG. The purpose of this study is to evaluate an investigational drug, EG-70. The safety and effects of the investigational drug will be assessed for this study.

The GI Research Department seeks patients 18 to 75 years old with mild to moderate ulcerative colitis (UC) for a research study. The COLLECTiVE202 study is testing an investigational drug product called VE202, which is designed to rebalance the bacteria in your intestine and, when used in combination with your other UC treatment, return your intestinal tract to a healthier state.

The GI Research Department seeks adults ages 18+ with biopsy-confirmed celiac disease to evaluate an investigational drug designed to break down gluten in the stomach and improve control of celiac disease for people on a gluten-free diet.

If you occasionally experience celiac-related gastrointestinal symptoms, despite trying to follow a gluten-free diet, this study may be a good fit for you. Participants must have been on a gluten-free diet for at least the past 12 months.

The GI Research Department seeks adults ages 18-75 with GERD-associated heartburn symptoms who are taking a PPI 5-7 days/week and still experiencing heartburn. The investigational medication is a pre-biotic, lightly sweet liquid – just 1/3 teaspoon nightly. No pills or capsules.

You may be eligible for this study if you are 18-75 years old, taking a PPI and have an active email/internet access for filling out nightly questionnaires.

The University of Virginia Comprehensive Cancer Center seeks participants ages 18 and over with certain types of gastric cancer, esophageal cancer, biliary tract cancer and pancreatic ductal adenocarcinoma that have received and progressed on or after 1 or 2 prior lines of therapy for their cancer. In this study, you will receive an investigational trial drug named MK-1200. All trial participants will get MK-1200 but the dose of MK-1200 you receive will depend on when you join the trial and your type of cancer.